DAVID GINSBURG, MD
Medical Practice at Frank Lloyd Wright Dr, Ann Arbor, MI
License number
Michigan 4301049059
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301049059
Category
Osteopathic Medicine
Type
Hematology
License number
Michigan 4301049059
Category
Medical Practice
Type
Clinical Genetics (M.D.)
Address
Address
24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105
Phone
(734) 647-8906
(734) 936-2047
(734) 936-2047
Personal information
See more information about DAVID GINSBURG at radaris.comName
Address
Phone
37780 Hollyhead Dr, Farmington Hills, MI 48331
3550 Fox Hunt Dr, Ann Arbor, MI 48105
627 S Franklin St, Mount Pleasant, MI 48858
3560 Sturbridge Ct, Ann Arbor, MI 48105
30000 Wildbrook Dr, Southfield, MI 48034
Organization information
See more information about DAVID GINSBURG at bizstanding.comDavid Ginsburg MD
1500 E Medical Ctr Dr, Ann Arbor, MI 48109
Industry:
Genetic Medicine, Internist
Phone:
(734) 763-2532 (Phone)
David A. Ginsburg
David Ginsburg MD
3550 Fox Hunt Dr, Ann Arbor, MI 48105
Industry:
Non Commercial Research
Medical Doctor, Principal:
David Ginsburg (Medical Doctor, Principal)
Professional information
Dr. David Ginsburg, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
TAUBMAN CTR RECP C
1500 E Medical Center Dr SUITE 3RD, Ann Arbor 48109
(734) 936-5548 (Phone)
UNIVERSITY OF MICHIGAN
210 Washtenaw Ave SUITE 5028, Ann Arbor 48109
(734) 647-4808 (Phone), (734) 763-7672 (Fax)
1500 E Medical Center Dr SUITE 3RD, Ann Arbor 48109
(734) 936-5548 (Phone)
UNIVERSITY OF MICHIGAN
210 Washtenaw Ave SUITE 5028, Ann Arbor 48109
(734) 647-4808 (Phone), (734) 763-7672 (Fax)
Certifications:
Clinical Genetics, 2010, Hematology, 1984, Internal Medicine, 1981, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
TAUBMAN CTR RECP C
1500 E Medical Center Dr SUITE 3RD, Ann Arbor 48109
UNIVERSITY OF MICHIGAN
210 Washtenaw Ave SUITE 5028, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr SUITE 3RD, Ann Arbor 48109
UNIVERSITY OF MICHIGAN
210 Washtenaw Ave SUITE 5028, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Duke University
Graduated: 1977
Brigham and Womens Hospital
Presby Hosp
Dana Farbor Can Ctr
Duke University
Graduated: 1977
Brigham and Womens Hospital
Presby Hosp
Dana Farbor Can Ctr
David A Ginsburg, Ann Arbor MI
Specialties:
Internist
Address:
1500 E Medical Center Dr, Ann Arbor, MI 48109
3621 S State St, Ann Arbor, MI 48108
210 Washtenaw Ave, Ann Arbor, MI 48109
3621 S State St, Ann Arbor, MI 48108
210 Washtenaw Ave, Ann Arbor, MI 48109
Education:
Duke University, School of Medicine - Doctor of Medicine
Brigham & Women's Hospital - Residency - Internal Medicine
California Pacific Medical Center - Pacific Campus - Residency - Pathology
Brigham & Women's Hospital - Residency - Internal Medicine
California Pacific Medical Center - Pacific Campus - Residency - Pathology
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine), American Board of Medical Genetics Certification in Clinical Genetics (MD) (Medical Genetics)
David A Ginsburg, Ann Arbor MI
Specialties:
Internal Medicine, Hematology, Medical Oncology, Medical Genetics, Clinical Genetics, M.D.
Work:
University of Michigan Medical School
210 Washtenaw Ave, Ann Arbor, MI 48109
210 Washtenaw Ave, Ann Arbor, MI 48109
Education:
Duke University(1977)
Adamts13 Genes And Proteins And Variants, And Therapeutic Compositions And Methods Of Utilizing The Same
US Patent:
2009027, Nov 5, 2009
Filed:
Apr 13, 2009
Appl. No.:
12/422803
Inventors:
David Ginsburg - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - ANN ARBOR MI
International Classification:
A61K 38/46
US Classification:
424 9467
Abstract:
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
Adamts13 Genes And Proteins And Variants, And Therapeutic Compositions And Methods Of Utilizing The Same
US Patent:
2009030, Dec 10, 2009
Filed:
Apr 13, 2009
Appl. No.:
12/422809
Inventors:
David Ginsburg - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - ANN ARBOR MI
International Classification:
A61K 38/46, C12N 9/50
US Classification:
424 9467, 435219
Abstract:
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
Adamts13 Genes And Proteins And Variants And Therapeutic Compositions And Methods Utilizing The Same
US Patent:
7517522, Apr 14, 2009
Filed:
Jan 30, 2006
Appl. No.:
11/342461
Inventors:
David Ginsburg - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 38/48, C12N 9/48
US Classification:
424 9467, 435221
Abstract:
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
Methods And Compositions For Treating Bacterial Infection
US Patent:
8501722, Aug 6, 2013
Filed:
Jan 21, 2010
Appl. No.:
12/691286
Inventors:
David Ginsburg - Ann Arbor MI, US
Hongmin Sun - Columbia MO, US
Scott Larsen - South Lyon MI, US
Bryan Yestrepsky - Ann Arbor MI, US
Hongmin Sun - Columbia MO, US
Scott Larsen - South Lyon MI, US
Bryan Yestrepsky - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A01N 43/00, A61K 31/33
US Classification:
514183, 514267, 514257, 506 2, 544230, 544249
Abstract:
The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.
Peptide Mediated Enhancement Of Thrombolysis Methods And Compositions
US Patent:
5639726, Jun 17, 1997
Filed:
Sep 30, 1994
Appl. No.:
8/315461
Inventors:
Daniel A. Lawrence - Ann Arbor MI
David Ginsburg - Ann Arbor MI
Joseph D. Shore - Grosse Point Farms MI
William P. Fay - Ann Arbor MI
Steven T. Olson - Chicago IL
Daniel T. Eitzman - Ypsilanti MI
Dell Paielli - Wyandotte MI
David Ginsburg - Ann Arbor MI
Joseph D. Shore - Grosse Point Farms MI
William P. Fay - Ann Arbor MI
Steven T. Olson - Chicago IL
Daniel T. Eitzman - Ypsilanti MI
Dell Paielli - Wyandotte MI
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
Henry Ford Health System - Detroit MI
Henry Ford Health System - Detroit MI
International Classification:
A61K 3800, A61K 3802, C07K 500, C07K 700
US Classification:
514 12
Abstract:
The invention relates generally to peptides which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using peptides which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions useful in clot lysis.
Methods And Compositions For Detecting Variant Adamts13 Genes
US Patent:
7037658, May 2, 2006
Filed:
Aug 16, 2002
Appl. No.:
10/222334
Inventors:
David Ginsburg - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Gallia Levy - Ann Arbor MI, US
Assignee:
Regents of University of Michigan - Ann Arbor MI
International Classification:
C12O 1/68, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
435 6, 435 912, 536 232, 536 235
Abstract:
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
Transgenic Mice Expressing Apc Resistant Factor V
US Patent:
6066778, May 23, 2000
Filed:
Nov 6, 1996
Appl. No.:
8/746111
Inventors:
David Ginsburg - Ann Arbor MI
Jisong Cui - South Plains NJ
Jisong Cui - South Plains NJ
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12N 500, A61K 4900
US Classification:
800 2
Abstract:
The present invention relates to compositions and methods for the screening of compounds for anticoagulant activity. In particular, the present invention relates to non-human transgenic animals expressing activated protein C ("APC")-resistant factor V proteins which display a predisposition toward spontaneous thrombosis. The present invention also provides methods for using these transgenic animals to screen compounds for anticoagulant activity.